Search Results

Antibodies against the CD47 “don’t eat me” signal were shown in mice to be a safe and effective way to target five kinds of pediatric brain tumors, according to Stanford researchers.

Stanford researchers have developed a test that may help screen for cardiotoxicity in new chemotherapy drugs.

In the hope of creating better access to medical care, Stanford researchers have trained an algorithm to diagnose skin cancer.

Physicians often fail to recommend genetic testing to breast cancer patients at high risk for cancer-associated mutations. Improving access to genetic counseling about the testing process and results is a key priority.

Effective anti-tumor activity requires a systemic, rather than only a local, immune response at the tumor site. A Stanford study may help clinicians pinpoint why only some cancer patients respond to immunotherapies.

The developmental biologist was honored for helping to decode how Wnt signaling proteins affect embryonic development, cancer and the activity of tissue-specific adult stem cells that repair damage after injury or disease.

The work extends research by Stanford scientists who found that blocking CD47 might be useful in treating human cancer.

Monitoring cancer DNA in blood can predict recurrence and prognosis and drive treatment decisions. A Stanford study of 92 lymphoma patients suggests similar techniques may work for other tumors.

Kara Davis, Melissa Mavers and Liora Schultz awarded St. Baldrick’s Foundation grants.

Scientists have devised a way to destroy blood stem cells in mice without using chemotherapy or radiotherapy, both of which have toxic side effects.